Popelová O, Sterba M, Hasková P, Simůnek T, Hroch M, Guncová I, Nachtigal P, Adamcová M, Gersl V, Mazurová Y
Department of Pharmacology, Faculty of Medicine, Charles University in Prague, Simkova 870, Hradec Králové 500 38, Czech Republic.
Br J Cancer. 2009 Sep 1;101(5):792-802. doi: 10.1038/sj.bjc.6605192. Epub 2009 Jul 21.
Dexrazoxane (DEX, ICRF-187) is the only clinically approved cardioprotectant against anthracycline cardiotoxicity. It has been traditionally postulated to undergo hydrolysis to iron-chelating agent ADR-925 and to prevent anthracycline-induced oxidative stress, progressive cardiomyocyte degeneration and subsequent non-programmed cell death. However, the additional capability of DEX to protect cardiomyocytes from apoptosis has remained unsubstantiated under clinically relevant in vivo conditions.
Chronic anthracycline cardiotoxicity was induced in rabbits by repeated daunorubicin (DAU) administrations (3 mg kg(-1) weekly for 10 weeks). Cardiomyocyte apoptosis was evaluated using TUNEL (terminal deoxynucleotidyl transferase biotin-dUTP nick end labelling) assay and activities of caspases 3/7, 8, 9 and 12. Lipoperoxidation was assayed using HPLC determination of myocardial malondialdehyde and 4-hydroxynonenal immunodetection.
Dexrazoxane (60 mg kg(-1)) co-treatment was capable of overcoming DAU-induced mortality, left ventricular dysfunction, profound structural damage of the myocardium and release of cardiac troponin T and I to circulation. Moreover, for the first time, it has been shown that DEX affords significant and nearly complete cardioprotection against anthracycline-induced apoptosis in vivo and effectively suppresses the complex apoptotic signalling triggered by DAU. In individual animals, the severity of apoptotic parameters significantly correlated with cardiac function. However, this effective cardioprotection occurred without a significant decrease in anthracycline-induced lipoperoxidation.
This study identifies inhibition of apoptosis as an important target for effective cardioprotection against chronic anthracycline cardiotoxicity and suggests that lipoperoxidation-independent mechanisms are involved in the cardioprotective action of DEX.
右丙亚胺(DEX,ICRF - 187)是唯一临床上批准用于对抗蒽环类药物心脏毒性的心脏保护剂。传统上认为它会水解为铁螯合剂ADR - 925,并预防蒽环类药物诱导的氧化应激、进行性心肌细胞变性及随后的非程序性细胞死亡。然而,在临床相关的体内条件下,DEX保护心肌细胞免于凋亡的额外能力仍未得到证实。
通过反复给予柔红霉素(DAU)(每周3 mg·kg⁻¹,共10周)诱导兔慢性蒽环类药物心脏毒性。使用TUNEL(末端脱氧核苷酸转移酶生物素 - dUTP缺口末端标记)检测法以及半胱天冬酶3/7、8、9和12的活性评估心肌细胞凋亡。使用高效液相色谱法测定心肌丙二醛以及4 - 羟基壬烯醛免疫检测法检测脂质过氧化。
右丙亚胺(60 mg·kg⁻¹)联合治疗能够克服DAU诱导的死亡率、左心室功能障碍、心肌的严重结构损伤以及心肌肌钙蛋白T和I释放至循环系统。此外,首次表明DEX在体内对蒽环类药物诱导的凋亡提供显著且近乎完全的心脏保护,并有效抑制由DAU触发的复杂凋亡信号传导。在个体动物中,凋亡参数的严重程度与心脏功能显著相关。然而,这种有效的心脏保护作用并未伴随蒽环类药物诱导的脂质过氧化显著降低。
本研究确定抑制凋亡是有效对抗慢性蒽环类药物心脏毒性的重要心脏保护靶点,并表明脂质过氧化非依赖性机制参与了DEX的心脏保护作用。